Eli Lilly (LLY) Stock Rises 7% Year-to-Date with Major Catalysts Ahead
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowEli Lilly (NYSE: LLY) has increased 7% since January 2026, underperformed compared to the broader market. In Q1 2026, sales surged 56% year-over-year, largely from its GLP-1 drug sales, with Mounjaro up 125% and Zepbound up 80%. The company is preparing to submit a Biologics License Application for retatrutide, its next product, to the FDA early next year, targeting a 2027 launch. Eli Lilly's upcoming earnings release on August 5 may affect stock performance, especially since it currently has a high P/E ratio of 34 times earnings, indicating a potential price adjustment. This information matters for investors evaluating potential entry points in LLY stock.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- State Street Healthcare ETFs XLV and XBI: Cost, Performance Comparison
- XLV vs PBE: Comparing Two Healthcare ETFs for Investors
- JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
- Eli Lilly Delays FDA Filing for Retatrutide Weight-Loss Drug
- Trump's Generic Drug Tariffs to Hit 100% by August 2028
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
